These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20959591)

  • 21. Circulating microRNAs (miRNA) in serum of patients with prostate cancer.
    Mahn R; Heukamp LC; Rogenhofer S; von Ruecker A; Müller SC; Ellinger J
    Urology; 2011 May; 77(5):1265.e9-16. PubMed ID: 21539977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Risk Markers and Risk Assessments for Cardiovascular Disease.
    Thomas MR; Lip GY
    Circ Res; 2017 Jan; 120(1):133-149. PubMed ID: 28057790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating and urinary microRNAs in kidney disease.
    Lorenzen JM; Thum T
    Clin J Am Soc Nephrol; 2012 Sep; 7(9):1528-33. PubMed ID: 22580786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating microRNAs: emerging biomarkers of liver disease.
    Arrese M; Eguchi A; Feldstein AE
    Semin Liver Dis; 2015 Feb; 35(1):43-54. PubMed ID: 25632934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple biomarkers for predicting cardiovascular events: lessons learned.
    Wang TJ
    J Am Coll Cardiol; 2010 May; 55(19):2092-5. PubMed ID: 20447531
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.
    Zethelius B; Berglund L; Sundström J; Ingelsson E; Basu S; Larsson A; Venge P; Arnlöv J
    N Engl J Med; 2008 May; 358(20):2107-16. PubMed ID: 18480203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender-specific features of plasmatic and circulating cell alterations as risk factors in cardiovascular disease.
    Straface E; Lista P; Gambardella L; Franconi F; Malorni W
    Fundam Clin Pharmacol; 2010 Dec; 24(6):665-74. PubMed ID: 20636365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating cardiovascular markers and mediators in acute illness: an update.
    Beishuizen A; Hartemink KJ; Vermes I; Groeneveld AJ
    Clin Chim Acta; 2005 Apr; 354(1-2):21-34. PubMed ID: 15748596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple biomarkers and cardiovascular risk.
    Pfister R; Hellmich M
    N Engl J Med; 2008 Aug; 359(7):760; author reply 761. PubMed ID: 18703482
    [No Abstract]   [Full Text] [Related]  

  • 30. Circulating microRNAs in Cardiovascular Diseases.
    Orlicka-Płocka M; Gurda D; Fedoruk-Wyszomirska A; Smolarek I; Wyszko E
    Acta Biochim Pol; 2016; 63(4):725-729. PubMed ID: 27755614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of cardiovascular disease events.
    Wilson PW
    Cardiol Clin; 2011 Feb; 29(1):1-13. PubMed ID: 21257097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages.
    Sukata T; Sumida K; Kushida M; Ogata K; Miyata K; Yabushita S; Uwagawa S
    Toxicol Lett; 2011 Jan; 200(1-2):46-52. PubMed ID: 21035526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory biomarkers and cardiovascular risk: association or cause and effect?
    Rao M; Jaber BL; Balakrishnan VS
    Semin Dial; 2006; 19(2):129-35. PubMed ID: 16551290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases.
    Cracowski JL; Ormezzano O
    Eur Heart J; 2004 Oct; 25(19):1675-8. PubMed ID: 15451144
    [No Abstract]   [Full Text] [Related]  

  • 35. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction.
    Meder B; Keller A; Vogel B; Haas J; Sedaghat-Hamedani F; Kayvanpour E; Just S; Borries A; Rudloff J; Leidinger P; Meese E; Katus HA; Rottbauer W
    Basic Res Cardiol; 2011 Jan; 106(1):13-23. PubMed ID: 20886220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin D-dimer and cardiovascular risk.
    Lowe GD
    Semin Vasc Med; 2005 Nov; 5(4):387-98. PubMed ID: 16302161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for cardiovascular risk assessment.
    Wolfert RL
    MLO Med Lab Obs; 2009 May; 41(5):14-6. PubMed ID: 19526891
    [No Abstract]   [Full Text] [Related]  

  • 38. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation.
    Ferri N; Paoletti R; Corsini A
    Curr Opin Lipidol; 2006 Oct; 17(5):495-501. PubMed ID: 16960497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating microRNAs and hypertension--from new insights into blood pressure regulation to biomarkers of cardiovascular risk.
    Romaine SP; Charchar FJ; Samani NJ; Tomaszewski M
    Curr Opin Pharmacol; 2016 Apr; 27():1-7. PubMed ID: 26827149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Emerging risk factors for cardiovascular disease].
    Demant T
    Dtsch Med Wochenschr; 2004 Jan; 129(5):204-9. PubMed ID: 14735418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.